%0 Journal Article
%T The role of immune checkpoint inhibitors in the first-line treatment for patients with advanced biliary tract cancer: a systematic review and meta-analysis of randomized trials.
%A Vitale E
%A Rizzo A
%A Maistrello L
%A Nardulli P
%A Talienti T
%A Quaresmini D
%A De Summa S
%A Massafra R
%A Silvestris N
%A Brunetti O
%J Front Oncol
%V 14
%N 0
%D 2024
%M 39091909
%F 5.738
%R 10.3389/fonc.2024.1409132
%X <B>UNASSIGNED: </B>We performed a systematic review and meta-analysis to further explore the impact of the addition of immunotherapy to gemcitabine-cisplatin as first-line treatment for advanced biliary tract cancer (BTC) patients.<BR><B>UNASSIGNED: </B>Literature research was performed, and hazard ratio values and 95% confidence intervals were calculated. Heterogeneity among studies was assessed using the tau-squared estimator ( τ 2 )  . The total Cochrane Q test (Q) was also assessed. The overall survival rate, objective response rate, and progression-free survival in the selected studies were assessed.<BR><B>UNASSIGNED: </B>A total of 1,754 participants were included. Heterogeneity among the studies selected was found to be non-significant (p = 0.78; tau2 = 0, I2 = 0%). The model estimation results and the forest plot suggested that the test for the overall effect was significant (Z = -3.51; p< 0.01).<BR><B>UNASSIGNED: </B>The results of the current meta-analysis further confirm the role of immune checkpoint inhibitors plus gemcitabine-cisplatin as the new standard first-line treatment for advanced BTC patients.<BR><B>UNASSIGNED: </B>https://www.crd.york.ac.uk/prospero, identifier CRD42023488095.